{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-25-000208","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.240909+00:00","generated_at":"2026-05-16T14:50:17.384318+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Denali secures $275M royalty funding from Royalty Pharma on tividenofusp alfa","bullets":["Royalty Pharma pays $200M at close conditional on FDA accelerated approval by June 30, 2026.","Additional $75M due upon EMA approval by Dec 31, 2029; royalty rate 9.25% on worldwide net sales.","Royalty ceases at 3.0x multiple (2.5x if reached by Q1 2039); Denali retains full rights.","PDUFA target date for tividenofusp alfa BLA is April 5, 2026; MPS II (Hunter syndrome) therapy.","Denali CFO states funds advance platform and launch preparation without dilution."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-25-000208","json":"https://secwatch.observer/filing/0001714899-25-000208.json","markdown":"https://secwatch.observer/filing/0001714899-25-000208.md","text":"https://secwatch.observer/filing/0001714899-25-000208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/0001714899-25-000208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/dnli-20251204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:50:17.384318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}